Compositions of proteus vulgaris chondroitinase I and chondroitinase II

• US 5,716,617 A
• Filed: 04/24/1995
• Issued: 02/10/1998
• Est. Priority Date: 04/22/1994
• Status: Expired due to Fees

• Current Assignee: American Cyanamid Co (Pfizer Inc.)
• Original Assignee: American Cyanamid Co (Pfizer Inc.)
• Inventors: Gotto, John, Eul, Ursula, Khandke, Kiran M.
• Primary Examiner(s): Weber, Jon P.
• Application Number:
  US08/428,949
• Time in Patent Office: 1,023 Days
• Field of Search: 435/200, 435/201, 435/202, 424/94.61, 424/94.62
• US Class Current: 424/94.62
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C12N 9/88 Lyases (4.)
• CPC Class Codes: Y10S 435/873 Proteus

Abstract

Chondroitinase II, a protein having an isoelectric point of approximately 8.4-8.45 and an apparent molecular mass of 112 kDa when electrophoresed in a 4 to 20% gradient acrylamide gel in 25 mM Tris/192 mM glycine buffer at pH 8.5 in the presence of about 0.1% (w/v) SDS, has been isolated and purified. A process for the copurification by affinity chromatography of the chondroitinase I and chondroitinase II proteins produced by Proteus vulgaris is also provided. The proteins can be further purified by metal chelating chromatography. Therapeutic or surgical compositions of isolated chondroitinases I and II or the copurified mixture of chondroitinase I and II are also disclosed. These compositions are used in a method for selectively and completely disinserting the vitreous body from the neural retina of an eye.

Claims

1. A surgical composition consisting essentially of a mixture of Proteus vulgaris chondroitinase I Proteus vulgaris and chondroitinase II, wherein said composition is suitable for use in humans, and wherein said composition is essentially free of proteolytic degradation products of said chondroitinase I and chondroitinase II.

2. The surgical composition as defined in claim 1, further consisting essentially of a pharmaceutically acceptable excipient.

3. The surgical composition as defined in claim 2, wherein said excipient comprises dextrose and citrate buffer.

4. The surgical composition as defined in claim 2, further consisting essentially of a pharmaceutically acceptable diluent.

5. The surgical composition as defined in claim 4, wherein said diluent comprises a mixture of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, sodium citrate, and water.

6. The surgical composition as defined in claim 1, wherein said surgical composition is free of proteinaceous stabilizers.

30. A dosage unit form comprising a surgical composition as defined in claim 2, wherein the amount of said chondroitinase I is between about 150 and about 150 and about 1500 units.

31. The dosage unit form as defined in claim 30, comprising a lyophilized cake.

32. The dosage unit form comprising a lyophilized cake as defined in claim 31 and a diluent.

7. A surgical composition consisting essentially of a disinsertion effective amount of a mixture of Proteus vulgaris chondroitinase I and Proteus vulgaris chondroitinase II, wherein said composition is suitable for use in humans, and wherein said composition is essentially free of proteolytic degradation products of said chondroitinase I and chondroitinase II.

8. The surgical composition as defined in claim 7, wherein the amount of said chondroitinase I is between 1 and 10,000 units and the weight to weight ratio of chondroitinase I to chondroitinase II ranges from 9:

1 to 6;

4.

9. A surgical composition consistently essentially of a mixture of Proteus vulgaris chondroitinase I and Proteus vulgaris chondroitinase II, wherein said chondroitinase I and chondroitinase II are prepared by a copurification process comprising:

(a) preparing a clarified homogenate of induced P. vulgaris, said homogenate having a pH of 5.8 to 7.4;

(b) loading said homogenate onto a negatively charged cation exchange resin chromatographic support so that any positively charged proteins comprising chondroitinase I and chondroitinase II in said homogenate form a non-covalent bond with said negatively charged support;

(c) affinity-eluting, in pools, said chondroitinase proteins from said support with an aqueous solution of chondroitin sulfate at pH of 7.0-9.5;

(d) loading said affinity etched protein pools onto an anion exchange resin chromatographic support to yield an unbound eluate; and

(e) recovering said chondroitinase I and chondroitinase II proteins in said unbound elute, and wherein said composition is essentially free of proteolytic degradation products of said chondroitinase I and chondroitinase II.

10. The surgical composition as defined in claim 9, wherein said homogenate has a pH of 6.5-7.0 and a conductivity of 3 milliSiemens/cm or lower.

11. The surgical composition as defined in claim 10, wherein said chondroitin sulfate solution in step (c) has a pH of 8.5-9.0.

12. The surgical composition as defined in claim 9, wherein said homogenate loaded onto said cation exchange resin at step (b) is equilibrated to a pH of 8-9 before step (c).

13. The surgical composition as defined in claim 9, wherein the concentration of chondroitin sulfate in said chondroitin sulfate solution in step (c) is 0.2%-10% w/v.

14. The surgical composition as defined in claim 9, wherein step (e) comprises

(i) contacting said eluate from step (d) with a metal chelating affinity chromatography support to bind further said chondroitinase proteins,

(ii) eluting with an appropriate solvent, and

(iii) recovering said chondroitinase proteins.

15. The surgical composition as defined in claim 14, wherein said metal chelating affinity chromatography support comprises a chelating metal selected from the group consisting of zinc and nickel.

16. A surgical composition comprising a solution consisting essentially of a mixture of Proteus vulgaris chondroitinase I and Proteus vulgaris chondroitinase II, wherein said composition is suitable for use in humans, and wherein said composition is essentially free of proteolytic degradation products of said chondroitinase I and chondroitinase II.

17. The surgical composition as defined in claim 16, wherein said solution comprises a pharmaceutically acceptable buffered solution.

18. A surgical composition comprising copurified Proteus vulgaris chondroitinase I and chondroitinase II, wherein said composition is suitable for use in humans, and wherein said composition is essentially free of proteolytic degradation products of said chondroitinase I and chondroitinase II.

19. The surgical composition as defined in claim 18, further comprising a pharmaceutically acceptable excipient.

20. The surgical composition as defined in claim 19, wherein said excipient comprises dextrose and citrate buffer.

21. The surgical composition as defined in claim 19, further consisting essentially of a pharmaceutically acceptable diluent.

22. The surgical composition as defined in claim 21, wherein said diluent comprises a mixture of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, sodium citrate, and water.

23. The surgical composition as defined in claim 18, comprising a solution.

24. The surgical composition as defined in claim 23, wherein said solution comprises a pharmaceutically acceptable buffer.

25. A surgical composition comprising a disinsertion effective amount of copurified Proteus vulgaris chondroitinase I and chondroitinase II, wherein said composition is suitable for use in humans, and wherein said composition is essentially free of proteolytic degradation products of said chondroitinase I and chondroitinase II.

26. The surgical composition as defined in claim 25, wherein the amount of said chondroitinase I is between 1 and 10,000 units and the weight to weight ratio of chondroitinase I to chondroitinase II ranges from 9:

1 to 6;

4.

27. The dosage unit form comprising a surgical composition as defined in claim 25, wherein the amount of said chondroitinase I is between about 150 and about 1500 units.

28. The dosage unit form as defined in claim 27, comprising a lyophilized cake.

29. The dosage unit form comprising a lyophilized cake as defined in claim 28, and a diluent.

33. A therapeutic composition of matter for selectively and completely disinserting the ocular vitreous body from the neural retina of the human eye, by administering to the eye of a human an effective amount of said composition wherein said composition comprises an isolated and purified chondroitinase II protein having an amino acid sequence corresponding to SEQ ID NO:

2 and an isoelectric point of approximately 8.4-8.45, and an isolated and purified chondroitinase I protein having an amino acid sequence corresponding to SEQ ID NO;

1, and wherein said chondroitinase I and chondroitinase II are prepared by a copurification process comprising;

(a) preparing a clarified homogenate of induced P. vulgaris, said homogenate having a pH of 5.8 to 7.4%;

(b) loading said homogenate onto a negatively charged cation exchange resin chromatographic support so that any positively charged proteins comprising chondroitinase I and chondroitinase II in said homogenate form a non-covalent bond with said negatively charged support;

(c) affinity-eluting, in pools, said chondroitinase proteins from said support with an aqueous solution of chondroitin sulfate at pH of 7.0-9.5;

(d) loading said affinity eluted protein pools onto an anion exchange resin chromatographic support to yield an unbound eluate; and

(e) recovering said chondroitinase I and chondroitinase II proteins in said unbound elute and wherein said composition is essentially free of proteolytic degradation products of said chondroitinase I and chondroitinase II.

34. The therapeutic composition as defined in claim 33, wherein said chondroitinase II protein has an apparent molecular mass of 112 kDa when electrophoresed in a 4 to 20% gradient acrylamide gel in 25 mM Tris/192 mM glycine buffer at pH 8.5 in the presence of about 0.1% (w/v) SDS.

35. The therapeutic composition as defined in claim 33, wherein said chondroitinase II protein corresponds to the upper band of the doublet of FIG. 2, Lane D.

36. The therapeutic composition as defined in claim 33, wherein said composition is administered to said eye by means of intravitreal, subvitreal, sublenticular or posterior chamber administration.

37. The therapeutic composition as defined in claim 33, further comprising a pharmaceutically acceptable excipient.

38. The therapeutic composition as defined in claim 37, wherein said excipient comprises dextrose and citrate buffer.

39. The therapeutic composition as defined in claim 37, further comprising a pharmaceutically acceptable diluent.

40. The therapeutic composition as defined in claim 39, wherein said diluent comprises a mixture of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, sodium citrate, and water.

41. The therapeutic composition as defined in claim 37, comprising a lyophilized cake dosage unit form.

42. The therapeutic composition as defined in claim 33, wherein said composition is administered in the form of a pharmaceutically acceptable buffered solution.

43. The therapeutic composition as defined in claim 33, wherein the amount of said chondroitinase I is between I and 10,000 units and the weight to weight ratio of chondroitinase I to chondroitinase II ranges from 9:

1 to 6;

4.